Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era

Hematology/Oncology Clinics of North America

Volumn 25, Issue 5, 2011, Pages 1025-1048

  Jain, Nitin ^a   Van Besien, Koen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Allogeneic stem cell transplant; Chronic myelogenous leukemia; Imatinib; Tyrosine kinase inhibitors

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BUSULFAN; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERFERON; TREOSULFAN;

ALLOGENEIC STEM CELL TRANSPLANTATION; APHERESIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COMORBIDITY INDEX; COMPARATIVE EFFECTIVENESS; DONOR SELECTION; DRUG COST; DRUG EFFECT; DRUG TREATMENT FAILURE; EBMT SCORE; EUROPE; EVENT FREE SURVIVAL; GENE MUTATION; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA RELAPSE; MEXICO; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PATIENT MONITORING; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SCORING SYSTEM; SIBLING; SOUTH AND CENTRAL AMERICA; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 80755189388     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.09.003     Document Type: Review

References (127)

1. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344(14):1031-1037.
2. Bjorkholm M., Ohm L., Eloranta S., et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011, 29(18):2514-2520.
3. Fefer A., Buckner C.D., Thomas E.D., et al. Cure of hematologic neoplasia with transplantation of marrow from identical twins. N Engl J Med 1977, 297(3):146-148.
4. Clift R.A., Buckner C.D., Thomas E.D., et al. Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet 1982, 2(8299):621-623.
5. Goldman J.M., Baughan A.S., McCarthy D.M., et al. Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet 1982, 2(8299):623-625.
6. Speck B., Bortin M.M., Champlin R., et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984, 1(8378):665-668.
7. Gratwohl A., Baldomero H., Horisberger B., et al. Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002, 100(7):2374-2386.
8. Thomas E.D., Clift R.A., Fefer A., et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986, 104(2):155-163.
9. Crawley C., Szydlo R., Lalancette M., et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005, 106(9):2969-2976.
10. Goldman J.M., Szydlo R., Horowitz M.M., et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993, 82(7):2235-2238.
11. Robin M., Guardiola P., Devergie A., et al. A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 2005, 19(9):1613-1620.
12. Hansen J.A., Gooley T.A., Martin P.J., et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998, 338(14):962-968.
13. Goldman J.M., Majhail N.S., Klein J.P., et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 2010, 28(11):1888-1895.
14. Available at: Accessed September 27, 2011. http://seer.cancer.gov/statfacts/html/cmyl.html.
15. Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988, 108(6):806-814.
16. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78(8):2120-2130.
17. Buckner C.D., Stewart P., Clift R.A., et al. Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol 1978, 6(1):96-109.
18. Goldman J.M., Th'ng K.H., Park D.S., et al. Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukaemia in blast-cell transformation. Br J Haematol 1978, 40(2):185-195.
19. Reiffers J., Trouette R., Marit G., et al. Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases. Br J Haematol 1991, 77(3):339-345.
20. McGlave P.B., De Fabritiis P., Deisseroth A., et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994, 343(8911):1486-1488.
21. Khouri I.F., Kantarjian H.M., Talpaz M., et al. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone Marrow Transplant 1996, 17(5):775-779.
22. Deisseroth A.B., Zu Z., Claxton D., et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994, 83(10):3068-3076.
23. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76(12):2462-2465.
24. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86(5):2041-2050.
25. Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15(2):433-444.
26. Dazzi F., Szydlo R.M., Cross N.C., et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000, 96(8):2712-2716.
27. Guglielmi C., Arcese W., Dazzi F., et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002, 100(2):397-405.
28. Weiden P.L., Sullivan K.M., Flournoy N., et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304(25):1529-1533.
29. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75(3):555-562.
30. Slavin S., Naparstek E., Nagler A., et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995, 23(14):1553-1562.
31. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89(12):4531-4536.
32. Childs R., Epperson D., Bahceci E., et al. Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect. Br J Haematol 1999, 107(2):396-400.
33. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97(11):3390-3400.
34. Das M., Saikia T.K., Advani S.H., et al. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 2003, 32(2):125-129.
35. Or R., Shapira M.Y., Resnick I., et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003, 101(2):441-445.
36. Weisser M., Schleuning M., Ledderose G., et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant 2004, 34(12):1083-1088.
37. Kerbauy F.R., Storb R., Hegenbart U., et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 2005, 19(6):990-997.
38. Kebriaei P., Detry M.A., Giralt S., et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007, 110(9):3456-3462.
39. Champlin R., de Lima M., Kebriaei P., et al. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 2009, 9(Suppl 3):S261-S265.
40. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91(3):756-763.
41. Luo Y., Lai X.Y., Tan Y.M., et al. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia 2009, 23(6):1171-1174.
42. Poire X., Artz A., Larson R.A., et al. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma 2009, 50(1):85-91.
43. Raiola A.M., Van Lint M.T., Lamparelli T., et al. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol 2000, 109(4):716-721.
44. Bornhauser M., Kiehl M., Siegert W., et al. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. Br J Haematol 2001, 115(1):119-124.
45. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91(4):513-521.
46. Gratwohl A., Heim D. Current role of stem cell transplantation in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009, 22(3):431-443.
47. Bacher U., Klyuchnikov E., Zabelina T., et al. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004. Ann Hematol 2009, 88(12):1237-1247.
48. Giralt S.A., Arora M., Goldman J.M., et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007, 137(5):461-467.
49. Ruiz-Argüelles G.J., Gomez-Almaguer D., Morales-Toquero A., et al. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005, 36(12):1043-1047.
50. Gratwohl A., Baldomero H., Schwendener A., et al. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe-impact of cost considerations. Leukemia 2007, 21(3):383-386.
51. Hehlmann R., Berger U., Pfirrmann M., et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007, 109(11):4686-4692.
52. Bittencourt H., Funke V., Fogliatto L., et al. Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplant 2008, 42(9):597-600.
53. Saussele S., Lauseker M., Gratwohl A., et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010, 115(10):1880-1885.
54. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003, 102(4):1224-1231.
55. Suttorp M., Claviez A., Bader P., et al. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. Klin Padiatr 2009, 221(6):351-357.
56. Apperley J. CML in pregnancy and childhood. Best Pract Res Clin Haematol 2009, 22(3):455-474.
57. Palandri F., Castagnetti F., Testoni N., et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica 2008, 93(12):1792-1796.
58. Palandri F., Castagnetti F., Alimena G., et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009, 94(2):205-212.
59. Silver R.T., Cortes J., Waltzman R., et al. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica 2009, 94(5):743-744.
60. Jiang Q., Xu L.P., Liu D.H., et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011, 117(11):3032-3040.
61. Deininger M., Schleuning M., Greinix H., et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006, 91(4):452-459.
62. Lee S.J., Kukreja M., Wang T., et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008, 112(8):3500-3507.
63. Shimoni A., Kroger N., Zander A.R., et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003, 17(2):290-297.
64. Zaucha J.M., Prejzner W., Giebel S., et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2005, 36(5):417-424.
65. Oehler V.G., Gooley T., Snyder D.S., et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007, 109(4):1782-1789.
66. Hehlmann R., Hochhaus A., Baccarani M. Chronic myeloid leukaemia. Lancet 2007, 370(9584):342-350.
67. Brave M., Goodman V., Kaminskas E., et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008, 14(2):352-359.
68. Hazarika M., Jiang X., Liu Q., et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008, 14(17):5325-5331.
69. Kantarjian H., Shah N.P., Hochhaus A., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362(24):2260-2270.
70. Saglio G., Kim D.W., Issaragrisil S., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362(24):2251-2259.
71. Jabbour E., Cortes J., Kantarjian H., et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 2007, 110(2):340-344.
72. Shimoni A., Leiba M., Schleuning M., et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemia. Leukemia 2009, 23(1):190-194.
73. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27(35):6041-6051.
74. Velev N., Cortes J., Champlin R., et al. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 2010, 116(15):3631-3637.
75. Basak G., Torosian T., Snarski E., et al. Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia. Ann Transplant 2010, 15(2):68-70.
76. Sanchez-Guijo F.M., Lopez-Jimenez J., Gonzalez T., et al. Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia. Leuk Res 2009, 33(6):e20-e22.
77. Jabbour E., Cortes J., Santos F.P., et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 2011, 117(13):3641-3647.
78. Nicolini F.E., Basak G.W., Soverini S., et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 2011, [Epub ahead of print].
79. Nicolini FE, Mauro MJ, Martinelli G, et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood;114(26):5271-8.
80. Cortes J., Talpaz M., Bixby D., et al. A phase 1 trial of oral Ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. Blood 2010, 116:210.
81. Gratwohl A., Hermans J., Goldman J.M., et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998, 352(9134):1087-1092.
82. Passweg J.R., Walker I., Sobocinski K.A., et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004, 125(5):613-620.
83. Pavlu J., Kew A.K., Taylor-Roberts B., et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 2010, 115(20):4018-4020.
84. Artz A.S., Wickrema A., Dinner S., et al. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14(11):1209-1216.
85. Elmaagacli A.H., Beelen D.W., Opalka B., et al. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 1999, 94(2):384-389.
86. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23(22):5074-5087. Stem Cell Trialists' Collaborative Group.
87. Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007, 13(12):1461-1468.
88. Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000, 95(12):3702-3709.
89. Schmitz N., Eapen M., Horowitz M.M., et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006, 108(13):4288-4290.
90. Oehler V.G., Radich J.P., Storer B., et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2005, 11(2):85-92.
91. Weisdorf D.J., Anasetti C., Antin J.H., et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002, 99(6):1971-1977.
92. Arora M., Weisdorf D.J., Spellman S.R., et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 2009, 27(10):1644-1652.
93. Sanz J., Montesinos P., Saavedra S., et al. Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant 2010, 16(11):1589-1595.
94. Nagamura-Inoue T., Kai S., Azuma H., et al. Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis. Bone Marrow Transplant 2008, 42(4):241-251.
95. Socie G., Clift R.A., Blaise D., et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001, 98(13):3569-3574.
96. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002, 8(9):477-485.
97. Radich J.P., Gooley T., Bensinger W., et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003, 102(1):31-35.
98. Olavarria E., Siddique S., Griffiths M.J., et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007, 110(13):4614-4617.
99. Chakrabarti S., MacDonald D., Hale G., et al. T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 2003, 121(1):109-118.
100. von dem Borne P.A., Beaumont F., Starrenburg C.W., et al. Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab. Haematologica 2006, 91(11):1559-1562.
101. Holowiecki J., Giebel S., Wojnar J., et al. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. Br J Haematol 2008, 142(2):284-292.
102. Hughes T.P., Morgan G.J., Martiat P., et al. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991, 77(4):874-878.
103. Lin F., van Rhee F., Goldman J.M., et al. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996, 87(10):4473-4478.
104. Radich J.P., Gehly G., Gooley T., et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995, 85(9):2632-2638.
105. Kaeda J., O'Shea D., Szydlo R.M., et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006, 107(10):4171-4176.
106. Olavarria E., Kanfer E., Szydlo R., et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001, 97(6):1560-1565.
107. White H.E., Matejtschuk P., Rigsby P., et al. Establishment of the 1st World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 2010, 116(22):e111-e117.
108. Mackinnon S., Papadopoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86(4):1261-1268.
109. Dazzi F., Szydlo R.M., Craddock C., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000, 95(1):67-71.
110. Chalandon Y., Passweg J.R., Schmid C., et al. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant 2010, 45(3):558-564.
111. Craddock C., Szydlo R.M., Klein J.P., et al. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood 2000, 96(1):86-90.
112. Carpenter P.A., Snyder D.S., Flowers M.E., et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109(7):2791-2793.
113. Sillaber C., Herrmann H., Bennett K., et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 2009, 39(12):1098-1109.
114. Savani B.N., Montero A., Kurlander R., et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005, 36(11):1009-1015.
115. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002, 100(5):1590-1595.
116. Olavarria E., Ottmann O.G., Deininger M., et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003, 17(9):1707-1712.
117. Hess G., Bunjes D., Siegert W., et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005, 23(30):7583-7593.
118. Weisser M., Tischer J., Schnittger S., et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006, 91(5):663-666.
119. Drummond M.W., Marin D., Clark R.E., et al. Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol 2003, 123(3):479-483.
120. Hui C.H., Goh K.Y., White D., et al. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia 2003, 17(5):821-828.
121. Kreuzer K.A., Kluhs C., Baskaynak G., et al. Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol 2004, 124(2):195-199.
122. Perseghin P., Gambacorti-Passerini C., Tornaghi L., et al. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. Transfusion 2005, 45(7):1214-1220.
123. Gordon M.K., Sher D., Karrison T., et al. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma 2008, 49(3):531-537.
124. Bashir Q., De Lima M.J., McMannis J.D., et al. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma 2010, 51(8):1478-1484.
125. Sokal J.E., Cox E.B., Baccarani M., et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984, 63(4):789-799.
126. Hasford J., Pfirrmann M., Hehlmann R., et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998, 90(11):850-858.
127. Pavlu J., Szydlo R.M., Goldman J.M., et al. Three decades of transplantation for chronic myeloid leukemia: what have we learnt?. Blood 2011, 117(3):755-763.